USFDA closed the inspection after VAI classification, citing strong compliance and response to Form 483 observations.

• CEO highlights facility’s role in DDC, biologics, and complex injectables for GLP, 1 launches.
• The company’s five approved facilities and 1,200+ professionals support specialty pharma manufacturing.
• Closure validates commitment to quality, advancing the commercial phase with key partners.